Grufity logo
Grufity logo
GTBP

GTBP - GT Biopharma Inc. Stock Price, Fair Value and News

$9.20-2.43 (-20.89%)
Delayed as of 15 Sep 2026, 01:06 pm ET

GTBP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GTBP Price Action

Last 7 days

4795.8%

Last 30 days

3816.7%

Last 90 days

2511.1%

Trailing 12 Months

1350.6%

GTBP RSI Chart

GTBP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GTBP Valuation

Market Cap

524.6M

Price/Earnings (Trailing)

-110.22

Price/Sales (Trailing)

29.74

EV/EBITDA

-0.58

Price/Free Cashflow

-36.37

GTBP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GTBP Fundamentals

GTBP Revenue

Revenue (TTM)

455.0K

Rev. Growth (Yr)

52.63%

Rev. Growth (Qtr)

9.43%

GTBP Earnings

Earnings (TTM)

-4.8M

Earnings Growth (Yr)

85.02%

Earnings Growth (Qtr)

-59.48%

GTBP Profitability

Operating Margin

100.00%

EBT Margin

-3260.00%

Return on Equity

-133.37%

Return on Assets

-58.72%

Free Cashflow Yield

-2.75%

GTBP Investor Care

Shares Dilution (1Y)

1278.23%

Diluted EPS (TTM)

3.69

Revenue & Growth

How GT Biopharma Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025-455.0K--
2024-541.0K637.0K-
2023-240.0K436.0K-
201568.0K63.0K60.0K27.0K
2014-432.0K252.0K102.0K
2013476.0K610.0K673.0K495.0K
20127.0K118.7K230.3K342.0K
201114.8K18.5K22.3K26.0K
2010---11.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About GT Biopharma Inc.

GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
 CEO
 WEBSITEgtbiopharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2

GT Biopharma Inc. Frequently Asked Questions

GTBP is the stock ticker symbol of GT Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of GT Biopharma Inc. is 524.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, GTBP's PE ratio (Price to Earnings) is -110.22 and Price to Sales (PS) ratio is 29.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GTBP PE ratio will change depending on the future growth rate expectations of investors.